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OBJECTIVE — To evaluate the efﬁcacy of the group program PREDIAS for diabetes
prevention.
RESEARCH DESIGN AND METHODS — PREDIAS consists of 12 lessons and aims at
lifestyle modiﬁcation. The control group received written information about diabetes preven-
tion.Inthisstudy,atotalof182personswithanelevateddiabetesriskparticipated(aged56.3
10.1 years, 43% female, and BMI 31.5  5.3 kg/m
2).
RESULTS — After 12 months, weight loss was signiﬁcantly higher (P  0.001) in PREDIAS
than in the control group (3.8  5.2 vs. 1.4  4.09 kg). There were also signiﬁcant effects
(P  0.001) on fasting glucose (control group 1.8  13.1 mg/dl vs. PREDIAS 4.3  11.3
mg/dl), duration of physical activity per week (control group 17.9  63.8 min vs. PREDIAS
46.6  95.5 min; P  0.03), and eating behavior.
CONCLUSIONS — PREDIAS signiﬁcantly modiﬁed lifestyle factors associated with an ele-
vated diabetes risk.
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T
he prevalence of type 2 diabetes is
increasing worldwide. Diabetes is
associated with an increased risk
formorbidityandmortality(1,2).Meta-
analyses have shown that type 2 diabe-
tes can be effectively prevented or
delayed by lifestyle modiﬁcation (3,4).
We developed a group program (PRE-
DIAS) for the prevention of type 2 dia-
betes that is based on the Diabetes
Prevention Program (5,6). The aim of
this randomized controlled trial was to
evaluate in a 12-month follow-up the
efﬁcacy of PREDIAS with regard to the
primary outcome variable, weight re-
duction, as well as behavioral, meta-
bolic, and psychological outcomes as
secondary variables.
RESEARCH DESIGN AND
METHODS — PREDIASwascompared
with a control group whose members re-
ceived the PREDIAS group intervention
written information and patient materi-
als. Inclusion criteria were those aged
20–70 years with BMI 26 kg/m
2,i m -
paired glucose tolerance or impaired fast-
ing glucose, and an ability to read and
understand German. Exclusion criteria
were manifest diabetes or diagnosis of a
serious illness (e.g., cancer). All patients
gaveinformedconsent.Thestudywasap-
proved by the local ethics committee.
Individuals with an elevated diabetes
risk based on a high score (10) on the
Diabetes Risk Score (7) or according to
the assessment of a primary care physi-
cian were invited to a baseline examina-
tion. After a pool of 12–20 patients was
created, a centrally performed block ran-
domization (1:1) assigned subjects ran-
domly to the PREDIAS or the control
group.
The results refer to changes between
baseline and the 12-month follow-up
measurement.Patientsunderwentanoral
glucose tolerance test. Weight, height,
waist circumference, and blood pressure
were assessed by study nurses, who were
blinded to the treatment assignment of
the subjects. Also, lipids and A1C were
measured. Glucose was measured from
capillary blood samples.
Physical activity was assessed by a
physical activity questionnaire used in a
representative federal health survey in
Germany (8). Physical activity is reported
as minutes per week. The Three Factor
Eating Questionnaire, with the three
scales cognitive restraint of eating, disin-
hibition, and hunger, was used to mea-
sure psychological determinants of eating
behavior (9,10). Trait anxiety was mea-
suredbytheState-TraitAnxietyInventory
(11). High scores on the scales always in-
dicate a high parameter value.
The World Health Organization-Five
Well-BeingIndex(WHO-5)assessedpsy-
chological well-being (12), and the Cen-
ter for Epidemiologic Studies Depression
Scale (CES-D) measured depressive symp-
toms (13). Low scores on the WHO-5 indi-
cate reduced psychological well-being,
whereas high scores on the CES-D indicate
elevated depressive symptoms.
Statistical analysis
A power analysis showed that, assuming
an additional weight reduction of 2.5 
4.6 kg and a power of 1  0.90 (two–
sided 0.05), 73 participants per
group were appropriate. Calculating with
a nonevaluable rate of maximum 20%, a
total of 182 individuals (91 in each treat-
ment group) was needed.
An intention-to-treat analysis was
performed using the baseline observation
carried forward method. Statistical analy-
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DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1143Table 1—Baseline and 12-month follow-up results in the control group and the PREDIAS group
Control PREDIAS
Between-group
P-value
BMI (kg/m²)
Baseline 32.0  5.7 31.0  4.7
Endpoint 31.5  5.8 29.7  4.7
Change from baseline to endpoint 0.5  1.4 (P  0.002)* 1.3  1.7 (P  0.001)* 0.002
Weight (kg)
Baseline 93.6  19.3 92.1  16.5
Endpoint 92.2  19.4 88.3  15.9
Change from baseline to endpoint 1.4  4.0 (P  0.002)* 3.8  5.2 (P  0.001)* 0.001
Waist circumference (cm)
Baseline 106.3  13.7 106.8  13.7
Endpoint 105.9  14.1 102.7  12.5
Change from baseline to endpoint 0.4  6.2 (P  0.559)* 4.1  6.0 (P  0.001)* 0.001
Fasting glucose (mg/dl)
Baseline 105.5  12.4 105.7  12.4
Endpoint 107.3  14.3 101.4  11.3
Change from baseline to endpoint 1.8  13.1 (P  0.211)* 4.3  11.3 (P  0.001)* 0.001
2-h postprandial OGTT (mg/dl)
Baseline 138.5  34.9 133.1  36.2
Endpoint 130.3  36.1 125.8  41.3
Change from baseline to endpoint 8.2  36.9 (P  0.060)* 7.3  30.8 (P  0.041)* 0.865
A1C (%)
Baseline 5.7  0.6 5.7  0.5
Endpoint 5.8  0.5 5.7  0.4
Change from baseline to endpoint 0.1  0.4 (P  0.165)* 0.0  0.3 (P  0.203)* 0.060
Physical exercise (min/week)
Baseline 96.9  76.3 104.2  80.24
Endpoint 114.0  72.6 150.8  75.18
Change from baseline to endpoint 17.9  63.8 (P  0.035)* 46.6  95.5 (P  0.001)* 0.034
Total cholesterol (mg/dl)
Baseline 209.9  36.6 212.2  43.8
Endpoint 207.9  36.8 201.9  35.6
Change from baseline to endpoint 2.0  35.1 (P  0.607)* 10.3  35.9 (P  0.011)* 0.144
HDL cholesterol (mg/dl)
Baseline 53.5  13.2 55.9  14.1
Endpoint 51.3  14.5 54.6  14.9
Change from baseline to endpoint 2.2  9.4 (P  0.044)* 1.3  6.9 (P  0.104)* 0.479
Triglycerides (mg/dl)
Baseline 144.1  102.1 156.2  151.0
Endpoint 141.6  99.5 120.6  65.5
Change from baseline to endpoint 2.5  100.3 (P  0.823)* 35.6  136.8 (P  0.022)* 0.087
Systolic blood pressure (mmHg)
Baseline 139.1  15.9 141.8  18.6
Endpoint 138.1  15.3 137.2  17.1
Change from baseline to endpoint 1.0  16.7 (P  0.610)* 4.6  19.1 (P  0.035)* 0.217
Diastolic blood pressure (mmHg)
Baseline 87.3  9.7 88.5  10.5
Endpoint 85.2  12.3 84.1  10.4
Change from baseline to endpoint 2.1  12.6 (P  0.151)* 4.4  11.7 (P  0.001)* 0.255
TFEQ
Cognitive restraint
Baseline 10.2  4.3 10.0  4.0
Endpoint 11.7  4.7 13.9  4.2
Change from baseline to endpoint 1.5  3.0 (P  0.001)* 3.9  3.8 (P  0.001)* 0.0011
Disinhibition
Baseline 6.3  3.9 6.1  3.2
Endpoint 5.8  3.9 4.9  2.6
Change from baseline to endpoint 0.4  2.6 (P  0.247)* 1.2  2.7 (P  0.001)* 0.049
Continued on following page
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within-group differences and independent
t tests for between-group differences.
Program
The prevention program consisted of 12
lessons lasting 90 min each. During the
ﬁrst 8 weeks, eight core lessons were
given with one per week; the last four les-
sonswerebimonthlyboosterlessons.The
PREDIAS program, which is based on
self-management theory, was conducted
in small groups (median size seven peo-
ple). PREDIAS was delivered by either di-
abetes educators or psychologists. The
program comprised a set of transparen-
cies for the lessons and a curriculum for
the prevention manager. Each participant
received an exercise book, which con-
tained information about diabetes pre-
vention. This book also contained
resources for the participants such as a
table of caloric values and worksheets
(e.g., eating diaries and logbooks for
physical activity) for each lesson. More
details about PREDIAS can be accessed at
the homepage of the European Union
Project: Development and Implementa-
tion of a European Guideline and Train-
ing Standards for Diabetes Prevention
(IMAGE) at http://www.image-project.
eu/pdf/praedias (14).
RESULTS— A total of 182 partici-
pants were randomized (aged 56.3 
10.1years,43%female,education13.2
4.1 years, BMI 31.5  5.3 kg/m
2, fasting
glucose 105.7  12.8 mg/dl, and 2-h
postprandial postoral glucose 135.7 
35.8 mg/dl). There were no signiﬁcant
baseline differences between those in the
PREDIAS and the control group. The
study lost 17 participants (9.3%) to fol-
low-up. A dropout analysis showed no
signiﬁcant differences between partici-
pants who remained in the study and
those who dropped out.
After 12 months, there was a signiﬁ-
cant effect on body weight (Table 1). Par-
ticipants in the PREDIAS group had lost
3.8 kg of weight, whereas members of the
control group had reduced their weight
by 1.4 kg (P  0.001). An intention-to-
treat analysis yielded similar results (con-
trol group 1.3  3.9 kg vs. PREDIAS
group 3.6  5.1 kg; P  0.001). A sig-
niﬁcantly higher proportion of weight
was lost by those in the PREDIAS than in
the control group (4  5.4 vs. 1.6 
4.1%, respectively; P  0.002). Similar
results were obtained regarding BMI and
waist circumference.
Both groups increased their physi-
cal activity signiﬁcantly, but the in-
crease was signiﬁcantly greater in the
PREDIAS than in the control group.
Cognitive restraint of eating behavior
was signiﬁcantly more increased in the
PREDIASthaninthecontrolgroup,and
eating disinhibition was signiﬁcantly
more decreased in the PREDIAS than in
the control group. Members of the PRE-
DIAS group showed a signiﬁcant with-
in-group reduction on the hunger scale,
but there was no signiﬁcant between-
group difference.
There was a signiﬁcant effect of PRE-
DIASonfastingglucose;however,the2-h
postprandial glucose values and A1C did
not change signiﬁcantly between the
groups. Total cholesterol and triglycer-
ides,aswellassystolicanddiastolicblood
pressure, were signiﬁcantly reduced in
the PREDIAS group, whereas in the con-
trol group there was no substantial
change in these risk factors. However, the
between-group difference failed to reach
signiﬁcance.
In both groups, psychological well-
being increased, whereas anxiety and de-
pressive symptoms decreased. However,
except for anxiety, there were no signiﬁ-
cant differences between the two groups.
CONCLUSIONS — The PREDIAS
prevention program was able to reduce
weight and modify eating behavior and
physicalactivitysigniﬁcantly;thus,diabe-
tes risk was reduced. The magnitude of
these effects and the observed metabolic
changes were in the range of previously
published results of diabetes prevention
programs (3–5,15).
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Control PREDIAS
Between-group
P-value
Hunger
Baseline 4.9  3.8 4.5  3.4
Endpoint 4.7  3.8 3.4  3.1
Change from baseline to endpoint 0.2  2.7 (P  0.434)* 1.1  3.1 (P  0.002)* 0.066
Psychological well-being by WHO-5
Baseline 14.3  4.9 15.3  5.1
Endpoint 14.3  5.1 16.7  4.8
Change from baseline to endpoint 0.0  4.2 (P  0.901)* 1.4  3.9 (P  0.015)* 0.101
Depression by CES-D
Baseline 13.7  8.2 12.0  9.5
Endpoint 11.4  7.8 9.8  7.5
Change from baseline to endpoint 2.3  6.8 (P  0.009)* 2.2  7.7 (P  0.031)* 0.876
Trait Anxiety by STAI
Baseline 39.5  9.8 38.5  10.4
Endpoint 38.5  9.5 34.5  9.5
Change from baseline to endpoint 1.0  6.1 (P  0.142)* 3.5  7.1 (P  0.001)* 0.023
Data are means  SD. *P  within group test. OGGT, oral glucose tolerance test; STAI, State-Trait Anxiety Inventory; TFEQ, Three Factor Eating Questionnaire.
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